Elan Pharmaceuticals

Applied Molecular Elan Pharmaceuticals. Mosaic Technologies. SurroMed... 

Elan Pharmaceutical Research Corporation Eli Lilly and Company Glaxo Wellcome, Inc. 

NanoCrystal Technology Technical Data Sheet, Published by Elan Pharmaceutical, 2004. 

Elan Pharmaceuticals. Sonata (zaleplon) Capsules. 11/26/2001. Philadelphia, Wyeth Laboratories. 

Zanaflex is a registered trademark of Elan Pharmaceuticals Zoloft is a registered trademark of Pfizer Inc. Zomig is a registered trademark of AstraZeneca Zydone is a registered trademark of Endo Pharmaceuticals Inc. 

Myobloc Botulinum toxin type B Elan Pharmaceuticals... 

Assignee Elan Pharmaceuticals, Inc. and Pharmacia Upjohn Company... 

Elan Pharmaceuticals, Inc. and Pharmacia Upjohn Company Eli Lilly and Company Endorecherche, Inc. Pty. Ltd Fujisawa Pharmaceutical Co., Ltd... 

Elan Pharmaceuticals is developing SNX-111 (Ziconotide), the synthetic equivalent of cD-Conopeptide-MVIlA, found in the venom of the predatory marine snail Conus magus, for the treatment of severe pain and ischemia by the intrathecal or intravenous routes. The peptide has the structure H- Cys-Lys-Gly-Lys-Gly-Ala-Lys- Cys-Ser-Arg-Leu-Met-Tiy-Asp- Cys Cys-Thr-Gly-Ser- Cys-Arg-Ser-Gly-Lys- Cys-NH2cyclic(l 16),(8-20),(15-25)-tris(disulfide), which does not make it an... 

Elan Pharmaceuticals has developed the Spiros S2 inhaler which features the use of beads to disperse the powders on inhalation. Still under development, the results from testing show that Spiros S2 is a high dispersion efficiency inhaler capable of delivering drugs... 

Case study Bayer AG versus Elan Pharmaceutical Research Corporation... 

Following the successful outcomes of the studies of murine A/342 immunization in several laboratories, clinical trials were initiated. The immunogen used in these studies, AN-1792 (Elan Pharmaceuticals/Wyeth), contained synthetic A/342 in combination with an adjuvant (QS-21). Two Phase I studies were undertaken to evaluate the safety and tolerability of AN-1792 in patients with AD. The first was a single-dose study with three escalating A/342 dosage levels, but with a fixed adjuvant concentration. There were eight patients per dose level and a six-week period between escalations. The second Phase I study was a multi-dose (for both A/342 and QS-21 adjuvant), dose-escalation study, with a two to three month interval between each dose level. 

Townsend, Raymond J. Elan Pharmaceuticals, 7475 Lusk Boulevard, San Diego, CA 9212, USA. Email ray.townsend elan.com... 

Subcutaneous still remains the predictable and controllable route of delivery for peptides and macromolecules. However, there is need for greater convenience and lower cost for prolonged and repeated delivery. An example of refinement of subcutaneous delivery is MEDIPAD (Elan Pharmaceutical Technologies), which is a combination of patch concept and a sophisticated miniaturized pump operated by gas generation. It was described in the report on transdermal drug delivery. 

As a dynamic international scientist and businessman. Dr. Knablein served as consultant for global players, among them Baxter, Hoechst and Elan Pharmaceuticals focusing on fast-track product development, time-to-market reduction and imple-... 

The authors would also like to thank Professors Reinhard Miller (Max-Planck Institute, Potsdam/Golm, Germany), Egon Matijevic, Larry Eno (Clarkson University, Potsdam, NY, USA), Dr. Niels Ryde (Elan Pharmaceutical, Inc., King of Prussia, PA, USA), and Dr. Andrei Dukhin (Dispersion Technology, Inc., Mt. Kisco, NY, USA) for valuable comments, suggestions and discussions. 

Dale Shenk, Ph.D., at Elan Pharmaceuticals in San Francisco reported that the initial results of vaccination were very promising (Psychiatric Mews, August 18,2000). Unfortunately, he stopped the trial because of central nervous system inflammation in some of the subjects. There is still hope that a P-amyloid vaccine might eventually be a safe and effective treatment for AD, and many are pursuing research in this direction. Some peptides that bind to amyloid plaques are not toxic to human neurons in tissue culture. Other investigators are developing compounds that inhibit the enzymes involved in the production of P-amyloid, namely, P- and y-secretase. 

---